Corcept Reports No New Safety Signals in BELLA Trial
Corcept Therapeutics said no new safety signals were identified in the BELLA trial for its Lifyorli combination.
Corcept Therapeutics said no new safety signals were identified in the BELLA trial for its Lifyorli combination.